We are a drug delivery and product development company that partners with pharmaceutical companies to develop innovative products that have IP protection and/or market exclusivity, and to provide practical solutions to challenging product development problems using our multiple proprietary drug delivery technology platforms.
Our technologies are designed and developed to offer solutions to potential formulation and manufacturing issues, ensure product quality, mitigate risk, reduce manufacturing cost, improve patient compliance and reduce development time including time-to-clinic and time-to-market.
Isaac Ghebre-Sellassie, Ph.D. – Founder and President - Isaac has over 30 years of pharmaceutical executive and managerial experience. He has published extensively, including editing three books - Pharmaceutical Pelletization Technology, Multiparticulate Oral Drug delivery, and Pharmaceutical Extrusion Technology. He was the first scientist to utilize hot melt extrusion (HME) to enhance the solubility of a poorly drug substance for a product that was approved by the FDA in 1997. His in-depth knowledge of the fundaments of twin screw extrusion technology coupled with his expertise in formulation science has led him to develop a breakthrough abuse deterrent formulation technology platform that resists all forms of dosage form tampering with the potential to reduce or eliminate all forms of drug abuse. He is holder of 23 patents, and has been involved in the development of over 20 drug products.
Hibre Terefe, Ph.D. - Vice President, R & D - Hibre has over 15 years of academic and industrial research and development experience. He has extensive expertise in twin screw extrusion technologies, including hot melt extrusion as applied to solubility enhancement, modified release and tamper resistance products. His expertise in the area has helped him to contribute significantly in the development of abuse deterrent formulations for which he is a co-inventor.
Yatindra Joshi, Ph.D., MBA - Yatindra is founder of YMJ Consultants LLC and is a member of the Board of Tapemark, Cutis Pharmaceuticals, Virtus Pharmaceuticals, and InvaGen Pharmaceuticals. He is a seasoned executive with 31 years of pharmaceutical R&D experience and a unique combination of strong business and technical skills. Yatindra has authored 29 publications and has 19 patents.
Lawrence Bell, JD, MBA - Larry is a Partner and Co-head of the firm’s corporate practice group at Golenbock, Eiseman, Assor, Bell and Peskoe LLP. His practice focuses on the representation of private equity funds and strategic investors in international and domestic mergers, acquisitions, public and private capital raising transactions. He works with companies and funds and other investors in the fields of new media, technology, including companies engaged in the development of proprietary software, systems, information technology, medical devices and bio-pharmaceuticals.